In Brazil, Ministry of Health incorporates Pazopanib and Sunitinib to the Health Unic System

On December 28, the Ministry of Health published Regulation 91, which incorporates the Pazopanib and the Sunitinib to the Sistema Único de Saúde (SUS) for the treatment of patients with Renal Carcinoma of clear metastatic cell (CCRm). The measure will come into full effect in 180 days. The Sunitinib has been approved by the Agência Nacional de Vigilância Sanitária (ANVISA) for the last 12 years and the Pazopanib for the last 7 years. Both were only covered by the health plans in the last four years.

The Comissão Nacional de Incorporação de Tecnologias (National Commission for the Incorporation of Technology) of SUS (CONITEC)’s decision to not incorporate either of the medications, maintaining the stance of only offering treatment to these patients with Interferon, was challenged by specialist at SBOC in a Public Hearing through possible statements from the society (health professionals or not) backing the proposal to incorporate Sunitinib or Pazopanib in the treatment of patients who carry the Renal Carcinoma of clear metastatic cell.

In Brazil, the majority of cases of patients with cancer in the public health system had to wait longer to gain access to the numerous different medicines proved effective that could give higher life quality and expectation. For the patients in the public system, the treatments available today, the Interferon-alfa, was not associated with better overall survival or demonstrated significant evidence of improved quality of life and/or relief of symptoms beyond the elevated toxicity, complex dosage, and the objective response rates of less than 20%.

“Brazil has over 6,000 estimated new cases of kidney cancer per year. And, even though it is not one of the most prevalent tumors in our country, 40% of the diagnosed population in later stages of the disease only had at their disposal a treatment that is ineffective and has not been used in numerous other countries for over a decade. This makes this approval a unique victory for Oncology in our country,” declared Dr. Sergio Simon, the president of the SBOC, in their official website.